432 related articles for article (PubMed ID: 16116070)
1. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol.
Dessy C; Saliez J; Ghisdal P; Daneau G; Lobysheva II; Frérart F; Belge C; Jnaoui K; Noirhomme P; Feron O; Balligand JL
Circulation; 2005 Aug; 112(8):1198-205. PubMed ID: 16116070
[TBL] [Abstract][Full Text] [Related]
2. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization.
Dessy C; Moniotte S; Ghisdal P; Havaux X; Noirhomme P; Balligand JL
Circulation; 2004 Aug; 110(8):948-54. PubMed ID: 15302798
[TBL] [Abstract][Full Text] [Related]
3. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide.
Gupta S; Wright HM
Cardiovasc Ther; 2008; 26(3):189-202. PubMed ID: 18786089
[TBL] [Abstract][Full Text] [Related]
4. Nebivolol, a vasodilating selective beta(1)-blocker, is a beta(3)-adrenoceptor agonist in the nonfailing transplanted human heart.
Rozec B; Erfanian M; Laurent K; Trochu JN; Gauthier C
J Am Coll Cardiol; 2009 Apr; 53(17):1532-8. PubMed ID: 19389564
[TBL] [Abstract][Full Text] [Related]
5. No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.
Chlopicki S; Kozlovski VI; Gryglewski RJ
J Physiol Pharmacol; 2002 Dec; 53(4 Pt 1):615-24. PubMed ID: 12512696
[TBL] [Abstract][Full Text] [Related]
6. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation beta-blocker.
Ignarro LJ
Blood Press Suppl; 2004 Oct; 1():2-16. PubMed ID: 15587107
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells.
Ladage D; Brixius K; Hoyer H; Steingen C; Wesseling A; Malan D; Bloch W; Schwinger RH
Clin Exp Pharmacol Physiol; 2006 Aug; 33(8):720-4. PubMed ID: 16895546
[TBL] [Abstract][Full Text] [Related]
8. Neither K+ channels nor PI3K/Akt mediates the vasodilative effect of nebivolol on different types of rat arteries.
Wang Y; Zhang M; Liu Y; Li J; Song E; Niu L; Cheng N
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):332-8. PubMed ID: 19903983
[TBL] [Abstract][Full Text] [Related]
9. Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action.
Kalinowski L; Dobrucki LW; Szczepanska-Konkel M; Jankowski M; Martyniec L; Angielski S; Malinski T
Circulation; 2003 Jun; 107(21):2747-52. PubMed ID: 12742996
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide mechanisms of nebivolol.
Maffei A; Lembo G
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):317-27. PubMed ID: 19443516
[TBL] [Abstract][Full Text] [Related]
11. Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.
Ignarro LJ
Cardiovasc Ther; 2008; 26(2):115-34. PubMed ID: 18485134
[TBL] [Abstract][Full Text] [Related]
12. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol.
Parenti A; Filippi S; Amerini S; Granger HJ; Fazzini A; Ledda F
J Pharmacol Exp Ther; 2000 Feb; 292(2):698-703. PubMed ID: 10640308
[TBL] [Abstract][Full Text] [Related]
13. ENOS is not activated by nebivolol in human failing myocardium.
Brixius K; Song Q; Malick A; Boelck B; Addicks K; Bloch W; Mehlhorn U; Schwinger RH
Life Sci; 2006 Aug; 79(13):1234-41. PubMed ID: 16716362
[TBL] [Abstract][Full Text] [Related]
14. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: Role of antioxidant activity.
Mason RP; Kubant R; Jacob RF; Walter MF; Boychuk B; Malinski T
J Cardiovasc Pharmacol; 2006 Jul; 48(1):862-9. PubMed ID: 16891916
[TBL] [Abstract][Full Text] [Related]
15. Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta.
Rozec B; Quang TT; Noireaud J; Gauthier C
Br J Pharmacol; 2006 Apr; 147(7):699-706. PubMed ID: 16474420
[TBL] [Abstract][Full Text] [Related]
16. Effects of nebivolol on vascular endothelial and myocardial function in diabetes mellitus.
Doggen K; Fransen P; Lemmens K; De Keulenaer GW
J Cardiovasc Pharmacol; 2011 Jul; 58(1):56-64. PubMed ID: 21499118
[TBL] [Abstract][Full Text] [Related]
17. Short-term treatment with a beta-blocker with vasodilative capacities improves intrarenal endothelial function in experimental renal failure.
Gschwend S; Haug MB; Nierhaus M; Schulz A; Vetter R; Kossmehl P; Orzechowski HD; Scholze J; Rothermund L; Kreutz R
Life Sci; 2009 Sep; 85(11-12):431-7. PubMed ID: 19635487
[TBL] [Abstract][Full Text] [Related]
18. The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery.
Georgescu A; Pluteanu F; Flonta ML; Badila E; Dorobantu M; Popov D
Eur J Pharmacol; 2005 Jan; 508(1-3):159-66. PubMed ID: 15680267
[TBL] [Abstract][Full Text] [Related]
19. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
Brodde OE; Philipp T
Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
[TBL] [Abstract][Full Text] [Related]
20. Improvement of left ventricular diastolic function induced by β-blockade: a comparison between nebivolol and metoprolol.
Fang Y; Nicol L; Harouki N; Monteil C; Wecker D; Debunne M; Bauer F; Lallemand F; Richard V; Thuillez C; Mulder P
J Mol Cell Cardiol; 2011 Aug; 51(2):168-76. PubMed ID: 21640121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
